|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:antineoplastic_agent
gptkb:antiprotozoal_drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2002
|
|
gptkbp:ATCCode
|
L01XX26
|
|
gptkbp:CASNumber
|
58066-85-6
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
gptkb:alkylphosphocholine
|
|
gptkbp:chemicalFormula
|
C21H46NO4P
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:discoveredBy
|
gptkb:Asta_Medica
|
|
gptkbp:KEGGID
|
D02173
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
induces apoptosis
disrupts cell membrane
|
|
gptkbp:molecularWeight
|
407.6 g/mol
|
|
gptkbp:origin
|
gptkb:Germany
|
|
gptkbp:otherName
|
gptkb:hexadecylphosphocholine
gptkb:miltefosine
|
|
gptkbp:PubChem_CID
|
gptkb:DB09031
3599
CHEMBL1200982
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
vomiting
diarrhea
gastrointestinal disturbance
teratogenicity
|
|
gptkbp:UNII
|
1M03QO1Z69
|
|
gptkbp:usedFor
|
gptkb:leishmaniasis
gptkb:cancer
gptkb:visceral_leishmaniasis
|
|
gptkbp:bfsParent
|
gptkb:miltefosine
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Miltefos
|